Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.50 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.43 |
| ▸ | STS | P08842 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1245750 | 0.95 | TAS1R3 (0.54) | TAS1R3TAS1R1TAS1R2MTNR1AMTNR1B | |
| SCHEMBL1457549 | 0.89 | TAS1R3 (0.57) | TAS1R3TAS1R1TAS1R2MTNR1AMTNR1B | |
| SCHEMBL10668579 | 0.87 | ALDH1A1 (0.58) | TSHRALDH1A1LMNATP53L3MBTL1 | |
| SCHEMBL11055737 | 0.87 | NR5A1 (0.54) | TSHRALDH1A1LMNATP53L3MBTL1 | |
| SCHEMBL28264160 | 0.87 | ALDH1A1 (0.54) | TSHRALDH1A1LMNATP53L3MBTL1 | |
| SCHEMBL21384547 | 0.87 | ALDH1A1 (0.54) | TSHRALDH1A1LMNATP53L3MBTL1 | |
| SCHEMBL1245122 | 0.86 | TAS1R3 (0.61) | TAS1R3TAS1R1TAS1R2MTNR1AMTNR1B | |
| SCHEMBL16672556 | 0.83 | L3MBTL1 (0.57) | MTNR1AMTNR1BTSHRALDH1A1LMNA | |
| SCHEMBL10486641 | 0.83 | TSHR (0.57) | TSHRALDH1A1LMNAL3MBTL1MAPK1 | |
| SCHEMBL28292308 | 0.83 | TSHR (0.57) | TSHRALDH1A1LMNAL3MBTL1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2292224-B1 | Derivatives of lactiosole for preventing or treating diabetes | SYMRISE AG (DE) | 2018-03-07 | — | — | EP | claimed |
| US-8592621-B2 | Precursor compounds of sweet taste receptor antagonists for the prevention or treatment of disease | SYMRISE AG (DE) | 2013-11-26 | — | — | US | claimed |
| US-20110045069-A1 | PRECURSOR COMPOUNDS OF SWEET TASTE RECEPTOR ANTAGONISTS FOR THE PREVENTION OR TREATMENT OF DISEASE | SYMRISE GMBH CO. KG (DE) | 2011-02-24 | — | — | US | claimed |
| EP-2292224-B1 | Derivatives of lactiosole for preventing or treating diabetes | SYMRISE AG (DE) | 2018-03-07 | — | — | EP | disclosed |
| US-8592621-B2 | Precursor compounds of sweet taste receptor antagonists for the prevention or treatment of disease | SYMRISE AG (DE) | 2013-11-26 | — | — | US | disclosed |
| EP-2292224-A1 | Precursor compounds of sweet receptor antagonists for preventing or treating diabetes | Symrise AG (DE) | 2011-03-09 | — | — | EP | disclosed |
| EP-2292224-A1 | Precursor compounds of sweet receptor antagonists for preventing or treating diabetes | Symrise AG (DE) | 2011-03-09 | — | — | EP | disclosed |
| US-20110045069-A1 | PRECURSOR COMPOUNDS OF SWEET TASTE RECEPTOR ANTAGONISTS FOR THE PREVENTION OR TREATMENT OF DISEASE | SYMRISE GMBH CO. KG (DE) | 2011-02-24 | — | — | US | disclosed |
| US-20110045069-A1 | PRECURSOR COMPOUNDS OF SWEET TASTE RECEPTOR ANTAGONISTS FOR THE PREVENTION OR TREATMENT OF DISEASE | SYMRISE GMBH CO. KG (DE) | 2011-02-24 | — | — | US | disclosed |
| US-20110045069-A1 | PRECURSOR COMPOUNDS OF SWEET TASTE RECEPTOR ANTAGONISTS FOR THE PREVENTION OR TREATMENT OF DISEASE | SYMRISE GMBH CO. KG (DE) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110045069-A1 | PRECURSOR COMPOUNDS OF SWEET TASTE RECEPTOR ANTAGONISTS FOR THE PREVENTION OR TREATMENT OF DISEASE | TAS1R2, TAS2R5, TAS2R1 | TAS1R3 26/4885TAS1R1 19/4885TAS1R2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.